使用MCID来评估AD治疗干预措施的临床相关性
Jamie L Hamilton1, Rebecca L M Fuller1, Noopur Modi1
1CHDI Management/CHDI Foundation Princeton New Jersey USA.
Alzheimer's & dementia (New York, N. Y.)
|August 6, 2025
概括
确定在阿尔茨海默病 (AD) 中具有临床意义的益处对于新疗法至关重要. 最小临床重要差异 (MCID) 可以将治疗效应置于环境中,特别是使用患者在早期AD报告的结果.
科学领域:
- 神经科学和神经病学 神经科学和神经病学
- 临床试验和治疗方法
- 健康 结果 研究 研究 结果
背景情况:
- 最近FDA,MHRA和EMA对轻度认知障碍 (MCI) 和轻度阿尔茨海默病 (AD) 治疗的批准需要重新评估临床益处.
- 监管机构之间现有的不一致性凸显出需要对新的AD疗法进行一致的评估.
- 临床上重要的最小差异 (MCID) 的概念在定义痴呆症护理中的有意义的临床益处方面受到辩论.
研究的目的:
- 评估MCID对阿尔茨海默病 (AD) 研究中常见终点的应用.
- 确定MCID生成和应用的机会,以更好地评估AD中的治疗创新.
- 提出一致的MCID估计和在AD早期应用的建议.
主要方法:
- 透视性文章分析了MCID应用到标准AD结果措施的应用.
- 对临床益处的现有文献和监管考虑的审查.
- 重点是患者报告的结果 (PRO) 和观察数据用于MCID估计.
主要成果:
- 对于临床上有意义的AD进展变化,没有确立的黄金标准或共识.
- 基于的MCID可以将治疗效应的临床相关性置于背景.
- 患者报告的结果 (PROs) 对于在MCI和早期AD中定义MCID至关重要.
结论:
- 为了可靠地对AD群体进行MCID估计和比较,需要在结果测量中保持更大的一致性.
- 观察数据可以增强治疗影响的表征,并建立一个"基础真理"MCID.
- MCID估计可以通过将在AD中统计学上显著的治疗效应的重要性置于背景中来支持监管提交.
相关概念视频
01:22Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
01:26Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
01:11Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
01:16Clinical Trials
8.4K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.4K